TSRX mgt shot themselves in the foot; with SEC investigations, multiple dilution, claims of superiority unsubstantiated by the data, perpetual shelf registrations, un-ending insider sales, no news, no new partnerships, etc etc etc.
Other developmental antibiotic companies are flying high at new all-time highs (e.g. PYMX, NBY) while TSRX freefalls to new lows.